Last reviewed · How we verify

PF-06439535 (CN) — Competitive Intelligence Brief

PF-06439535 (CN) (pf-06439535-cn) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Selective pathway inhibitor; presumed anti-angiogenic agent. Area: Oncology.

discontinued Selective pathway inhibitor; presumed anti-angiogenic agent Not publicly disclosed; presumed to be VEGF pathway or related angiogenic target based on clinical trial design Oncology Live · refreshed every 30 min

Target snapshot

PF-06439535 (CN) (pf-06439535-cn) — Pfizer Inc.. Selective inhibitor blocking proteins that drive abnormal cell growth and division in cancer cells.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
PF-06439535 (CN) TARGET pf-06439535-cn Pfizer Inc. discontinued Selective pathway inhibitor; presumed anti-angiogenic agent Not publicly disclosed; presumed to be VEGF pathway or related angiogenic target based on clinical trial design

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Selective pathway inhibitor; presumed anti-angiogenic agent class)

  1. Pfizer Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). PF-06439535 (CN) — Competitive Intelligence Brief. https://druglandscape.com/ci/pf-06439535-cn. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: